 Cosmeceutical Assets Include Companys Lead Anti-inflammatory OTC Cosmeceutical Compound called LEATM Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine Companys Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEATM, Other Cosmeceuticals DOYLESTOWN, PA ACCESSWIRE August 24, 2021 Neuropathix, Inc. Neuropathix or the Company OTCQB:NPTX, a socially responsible pain management life sciences company, today announces the formation of Dermique Incorporated Dermique, a new wholly owned subsidiary to hold, manage, commercialize and market the intellectual property assets related to the companys cosmeceutical ingredients OTC IP. The Companys strategy in setting up Dermique is to set apart its product platforms and near-term revenue drivers for over-the-counter OTC use from its longer range pharmaceutical and drug discovery pipeline. 